Triple-Drug cocktail targets kidney cancer brain metastases

NCT ID NCT05048212

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—can help people with kidney cancer that has spread to the brain. The study will enroll 20 participants who have not had prior treatment for their brain metastases. The main goal is to see if the drug combination can delay the growth of brain tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab, Ipilimumab, and Cabozantinib (three drugs given together)
What this could lead to: If it works, this could offer a new treatment option for people with kidney cancer that has spread to the brain, potentially delaying the growth of brain tumors.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES RENAL CELL CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.